MX2021003234A - Inmunoglobulina de la molecula cd1d de acción dual. - Google Patents

Inmunoglobulina de la molecula cd1d de acción dual.

Info

Publication number
MX2021003234A
MX2021003234A MX2021003234A MX2021003234A MX2021003234A MX 2021003234 A MX2021003234 A MX 2021003234A MX 2021003234 A MX2021003234 A MX 2021003234A MX 2021003234 A MX2021003234 A MX 2021003234A MX 2021003234 A MX2021003234 A MX 2021003234A
Authority
MX
Mexico
Prior art keywords
cd1d
cells
immunoglobulins
immunoglobulin
relates
Prior art date
Application number
MX2021003234A
Other languages
English (en)
Inventor
Gruijl Tanja Denise De
Roeland Lameris
Der Vliet Johannes Jelle Van
Paul Willem Henri Ida Parren
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2021003234A publication Critical patent/MX2021003234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo de inmunología, más en particular al campo de restos de unión y/o inmunoglobulinas que se unen a CD1d humano, incluyendo anticuerpos y sus fragmentos que modifican funciones biológicas mediadas por CD1-d tales como la activación mejorada y la activación reducida de células T restringidas por CD1d, incluyendo las células T asesinas naturales y células T gamma-delta, y la modulación de la función de células que expresan CD1d; la invención también se refiere a inmunoglobulinas bi, tri o multiespecíficas que se unen a CD1d y un TCR gamma-delta y/o un objetivo tumoral; la invención se refiere además a preparaciones farmacéuticas y al uso de tales restos de unión mono, bi y tri o multiespecíficos y/o inmunoglobulinas en el tratamiento de enfermedades o trastornos.
MX2021003234A 2018-09-19 2019-09-19 Inmunoglobulina de la molecula cd1d de acción dual. MX2021003234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2021664 2018-09-19
PCT/NL2019/050624 WO2020060405A1 (en) 2018-09-19 2019-09-19 Dual acting cd1d immunoglobulin

Publications (1)

Publication Number Publication Date
MX2021003234A true MX2021003234A (es) 2021-07-16

Family

ID=63834616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003234A MX2021003234A (es) 2018-09-19 2019-09-19 Inmunoglobulina de la molecula cd1d de acción dual.

Country Status (12)

Country Link
US (2) US20210371525A1 (es)
EP (2) EP3853255A1 (es)
JP (2) JP2022501377A (es)
KR (1) KR20210062051A (es)
CN (2) CN113260629A (es)
AU (1) AU2019344300A1 (es)
BR (1) BR112021005184A8 (es)
CA (2) CA3113605A1 (es)
EA (1) EA202190773A1 (es)
MX (1) MX2021003234A (es)
SG (1) SG11202102629WA (es)
WO (2) WO2020060406A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3792283A1 (en) * 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN116209456A (zh) * 2020-08-14 2023-06-02 伽马三角洲疗法有限公司 多特异性抗TCRδ可变1抗体
CA3200826A1 (en) 2020-12-10 2022-06-16 Paul Willem Henri Ida PARREN Antibodies that bind gamma-delta t cell receptors
WO2022175414A1 (en) * 2021-02-17 2022-08-25 Adaptate Biotherapeutics Ltd. Multispecific anti-tcr delta variable 1 antibodies
EP4298125A1 (en) 2021-02-26 2024-01-03 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
WO2023037333A1 (en) * 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023067138A1 (en) * 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
CN116731166A (zh) * 2021-12-22 2023-09-12 北京世纪沃德生物科技有限公司 一种crp驼源单域抗体及其制备方法和应用
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
WO2023186905A1 (en) 2022-03-29 2023-10-05 LAVA Therapeutics N.V. A method of treating a hematological cancer following screening for cd1d positive tumor cells
EP4285926A1 (en) * 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
ES2537207T3 (es) 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
EP2766042A4 (en) * 2011-10-14 2015-05-27 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES AGAINST CD1d
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
CA2892193C (en) 2012-11-21 2018-06-19 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
JP6617138B2 (ja) * 2014-04-10 2019-12-11 ラヴァ・セラピューティクス・ベー・フェー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
KR20170021354A (ko) * 2014-07-02 2017-02-27 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법
EP3250608A1 (en) * 2015-01-27 2017-12-06 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
CN108289902B (zh) * 2015-09-09 2022-05-20 清华大学 作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂
KR102519861B1 (ko) * 2016-05-12 2023-04-10 아디셋 바이오, 인크. γδ T-세포 집단의 선택적 확장을 위한 방법 및 그의 조성물

Also Published As

Publication number Publication date
WO2020060406A1 (en) 2020-03-26
US20220111043A1 (en) 2022-04-14
JP2022501377A (ja) 2022-01-06
WO2020060405A1 (en) 2020-03-26
CA3113605A1 (en) 2020-03-26
BR112021005184A8 (pt) 2022-08-16
EP3853256A1 (en) 2021-07-28
BR112021005184A2 (pt) 2021-06-08
CA3113409A1 (en) 2020-03-26
SG11202102629WA (en) 2021-04-29
CN113260629A (zh) 2021-08-13
US20210371525A1 (en) 2021-12-02
KR20210062051A (ko) 2021-05-28
JP7457007B2 (ja) 2024-03-27
CN113272325A (zh) 2021-08-17
EP3853255A1 (en) 2021-07-28
JP2022501369A (ja) 2022-01-06
EA202190773A1 (ru) 2021-06-21
AU2019344300A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2021003234A (es) Inmunoglobulina de la molecula cd1d de acción dual.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
BR112018068678A2 (pt) anticorpos anti-mica
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
MX2020008684A (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
MX2023004333A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
EA202090372A1 (ru) Универсальные соединения авт и их применение
MX2021001508A (es) Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
BR112022007128A2 (pt) Ligação de proteínas nkg2d, cd16 e flt3
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
EA202190468A1 (ru) Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
AU2018273250A1 (en) A protein binding NKG2D, CD16 and a tumor-associated antigen
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.